

SUBJECT: EVALUATION ADVISORY COMMITTEE CHAIR REPORT

Category: For Information

Section A: Introduction

- This report provides the Board with an overview of the activities of the Evaluation Advisory Committee (EAC) since the interim Committee Chair last reported to the Board in June 2021. Since then, Professor James Hargreaves has joined the committee as the new EAC Chair.
- The EAC met virtually on 29 and 30 September to provide guidance on progress on on-going evaluations and approve updates to the multi-year evaluation workplan for Gavi 5.0; provide guidance on the Evaluation Operational Guidelines (EOGs) and on progress of the COVAX Facility and Advance Market Commitment (AMC) evaluability and evaluation design study and on the challenges identified at this early stage of the evaluation.
 - The EAC approved a revised multi-year evaluation workplan, which included a modified timeline for the development of the request for proposal (RFP) for the zero-dose evaluation. This has been postponed until Q1 2022 given the limited bandwidth and shifting priorities at the country level, largely due to the COVID-19 pandemic.
 - In relation to Gavi's EOGs, EAC members considered it important to remove the portion of Clause 7.5.1 in Gavi's Evaluation Policy that restricts EAC members from sitting on evaluation Steering Committees (SCs) on the basis that this prevents the EAC from ensuring the independence and quality of evaluations; and that participating throughout the evaluation process, including on SCs, would enable the EAC to maintain the oversight required to fulfil its Terms of Reference. The EAC Chair sought guidance on the proposed modification to the Evaluation Policy from the Governance Committee on 23 November 2021. The EAC will reconvene on 26 November 2021 to consider formally recommending an amendment to the policy. The EAC Chair will provide an update during the Board meeting on the outcome of these discussions.
 - The EAC provided guidance on how to strengthen reporting channels with the Board and increasing the visibility and utility of centralised evaluations. EAC members also noted that it would be worth engaging more with the PPC and to consider using technical briefings to share findings from evaluations.
 - On the COVAX Facility and AMC evaluability and evaluation design study, the EAC provided guidance to address challenges that include

the evolving and complex nature of COVAX; engagement of COVAX stakeholders and confirmation of evaluation scope. The EAC emphasised the importance of this critical evaluation and importance of engagement by key stakeholders in the process.

- As Committee membership will be modified at the end of 2021, the EAC also delegated authority to the Chair to identify focal points for centralised evaluations of strategic importance to the Board, on an as needed basis, drawing from the available pool of EAC members, prior to the next regular EAC meeting.
- The committee also held a closed session, focusing on EAC engagement on Gavi 5.0 evaluations and guidance on the EOGs.
- Recent evaluations have had their findings rapidly taken up to inform various strategies, policies, processes, and reporting requirements; for example: findings from the recent evaluations of the Fragility, Emergencies, Refugees policy and Private Sector Engagement approach were presented at the October 2021 PPC meeting as part of discussions on new or revised approaches. These were good examples of managing the timing of evaluations to optimise utility.
- An EAC representative and the EAC Chair are participating in a process led by a sub-committee of the Governance Committee to recruit new members to join the EAC to replace those moving on and to expand the size of the EAC.
- The EAC would like to recognise the work of outgoing EAC members, namely Zulfiqar Bhutta, Jeanine Condo, and Rafael Vilasanjuan and thank them for their service and for their contribution to the EAC and Gavi's centralised evaluations.
- The EAC Chair report is attached in the form of a presentation as Annex A and the EAC recommendations to the Board are attached as Annex B.

Annexes

Annex A: EAC Chair report

Annex B: EAC recommendations to Gavi Alliance Board

EVALUATION ADVISORY COMMITTEE CHAIR REPORT

BOARD MEETING

James Hargreaves

30 November – 2 December 2021, Virtual Meeting

Overview: Evaluations approved under Gavi 4.0

Evaluation	Year				
	2021	2022	2023	2024	2025
Evaluation of the Cold Chain Equipment Optimisation Platform (CCEOP)	◆				
Fragilities, Emergencies, Refugees Policy Evaluation	◆				
Pneumococcal Vaccine Advance Market Commitment evaluation	◆				
Supply and Procurement Strategy review	◆				
Private Sector Engagement Approach Evaluation	◆				
COVAX Facility and COVAX AMC evaluability, design and baseline evaluation	◆	◆	◆		
COVAX Facility and COVAX AMC multi-stage evaluation	◆	◆		◆	◆

2		Evaluation commissioning period
		Evaluation implementation and delivery period
	◆	Deliverable that needs to be seen by the EAC

Board meeting
30 November - 2 December 2021

Overview: Gavi 5.0 multi-year evaluation workplan

Evaluation	Year				
	2021	2022	2023	2024	2025
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities		◆	◆	◆	
Evaluation of the Operationalisation of Gavi's Strategy through Gavi's Policies, Programmatic Guidance and Use of Funding Levers	◆	◆			
Gavi's initial response to COVID-19	◆	◆			
Gavi 5.0 Mid-term evaluation	◆	◆	◆		
Gavi's contribution to sustainability of coverage post-transition			◆	◆	

	Evaluation commissioning period
	Evaluation implementation and delivery period
◆	Deliverable that needs to be seen by the EAC

Progress Update – Evaluations approved under 4.0

Evaluation	Progress Update
Evaluation of the Cold Chain Equipment Optimisation Platform (CCEOP)	<p>Draft final country reports (one each for Kenya, Guinea, Pakistan, including COVID-19 component) reviewed by EAC focal points – mid-July</p> <p>Draft final cross-country report (including Kenya, Guinea, Pakistan, Market Shaping and COVID-19 component) reviewed by EAC focal points early Sept (<i>met Gavi's quality standards</i>)</p> <p><i>Dissemination – 17 Nov 2021</i></p>
Fragilities, Emergencies, Refugees Policy Evaluation	<p>Draft final report reviewed by EAC focal points in August (<i>met Gavi's quality standards</i>)</p> <p><i>Dissemination – 19 Oct 2021</i></p>
Pneumococcal Vaccine Advance Market Commitment Evaluation	<p>Draft final report reviewed by EAC focal points end October (<i>fully met or exceeded Gavi's quality standards</i>)</p>

Progress Update – Evaluations approved under 4.0

Evaluation	Progress Update
COVAX Facility and COVAX AMC evaluability, design and baseline evaluation	Inception report reviewed end September Final report for evaluability and design study expected mid-December
Supply and Procurement Strategy review	EAC summary assessment, Evaluation Management Response (EMR) and final report posted on the Gavi website <i>(fully met or exceeded Gavi's quality standards)</i>
Private Sector Engagement Approach Evaluation	EAC summary assessment, EMR and final report posted on the Gavi website <i>(fully met or exceeded Gavi's quality standards)</i>

Progress Update – Evaluations approved under 5.0

Evaluation	Progress Update
Gavi's initial response to COVID-19	Service Provider selection – on-going Implementation to commence in December 2021
Evaluation of the Operationalisation of Gavi's Strategy through Gavi's Policies, Programmatic Guidance and Use of Funding Levers	Request for Proposal published on the Gavi website in early November Implementation to commence in January 2022
Gavi 5.0 Mid-term evaluation	Development of Terms of Reference underway Request for Proposal to finalised in Q1 2022
Evaluation of Gavi's contribution to reaching zero-dose children and missed communities	Terms of Reference to be developed in Q1 2022

Role of EAC on evaluation Steering Committees

- EAC discussed removing the portion of Clause 7.5.1 in Gavi's Evaluation Policy that restricts members from sitting on evaluation Steering Committees (SCs) on basis that this:
 - prevents the EAC from ensuring the independence and quality of evaluations; and
 - participating throughout the evaluation process, including on SCs, would enable the EAC to maintain the oversight required to fulfil its Terms of Reference.
- The Governance Committee provided guidance on the proposed modification at its meeting on 23 November 2021.
- A further discussion was planned for the EAC meeting on 26 November 2021 to consider whether to make a recommendation to the Board to amend the policy.

Thank you



REVIEW OF DECISIONS

EVALUATION ADVISORY COMMITTEE
29-30 September 2021, Virtual Meeting

Decision 1: Update on Planned Evaluations

The Gavi Alliance Evaluation Advisory Committee:

Approved the revised multi-year (2021-2025) centralised evaluation workplan attached as Annex A to Doc 05.

Decision 2: Delegation of Authority

The Gavi Alliance Evaluation Advisory Committee:

Delegated authority to the Chair of the Evaluation Advisory Committee to identify focal points for centralised evaluations of strategic importance to the Board, on an as needed basis, drawing from the available pool of EAC members, prior to the next regular EAC meeting.

Thank you

